Credit Suisse Double Downgrades Edge Therapeutics (EDGE) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
JMP Securities Downgrades Edge Therapeutics (EDGE) to Market Perform, 'Phase 3 NEWTON 2 trial failed to showbenefit with EG-1962'
March 28, 2018 11:12 AM EDTJMP Securities downgraded Edge Therapeutics (NASDAQ: EDGE) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Edge Therapeutics click here. For more ratings news on Edge Therapeutics click here.
Shares of Edge Therapeutics closed at $15.59 yesterday.
... MoreEdge Therapeutics (EDGE) Says DMC Recommended Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage be Stopped
March 28, 2018 7:07 AM EDTEdge Therapeutics, Inc. (Nasdaq: EDGE) today announced that a pre-specified interim analysis performed on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage (aSAH) demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the studys primary endpoint, if the study is fully enrolled.
The independent Data Monitoring Committee (DMC) recommended that the study be stopped based on its conclusion that the study has a low probability of meeting... More
